Similarly in 91 multiple myeloma patients treated with bortezomib or thalidomide lower BDNF levels during treatment were associated with CIPN by Common Terminology Criteria for Adverse Events (CTCAE), and a cut-point of 9.11 ng/ml was 76% sensitive and 71.4% specific to identify CIPN (17). This evidence concerns the gene BDNF and plasma cell myeloma.